Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response (Q45855437)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 June 2016

Language	Label	Description	Also known as
English	Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response	scientific article published on 21 June 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

phase I clinical trial

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Richard P Junghans

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Qiangzhong Ma

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Ritesh Rathore

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Erica M Gomes

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Anthony J Bais

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Agnes S Y Lo

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Mehrdad Abedi

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Robin A Davies

8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Howard J Cabral

9

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

A Samer Al-Homsi

10

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Stephen I Cohen

11

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

publication date

21 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

76

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

14

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

1257-1270

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Clinical evaluation of TRICOM vector therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Expression of glutamate carboxypeptidase II in human brain

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Is it safer CARs that we need, or safer rules of the road?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Chimeric antigen receptor T cells for sustained remissions in leukemia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23214

21 January 2018

Identifiers

10.1002/PROS.23214

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/27324746

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45855437&oldid=2143961325"